Achievement

Cervical Cancer(Vulva Cancer) Committee （Click to expand）

Predictors for pathological parametrial invasion in clinical stage IIB cervical cancer.
Matsuo K, Shimada M Nakamura K, Takei Y, Ushijima K, Sumi T, Ohara T, Yahata H, Mikami M, Sugiyama T.
Eur J Surg Oncol. 2019 Feb 18. pii: S0748-7983(19)30290-2. doi: 10.1016/j.ejso.2019.02.019.
Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival.
Matsuo K, Shimada M, Yamaguchi S, Kigawa J, Tokunaga H, Tabata T, Kodama J, Kawana K, Mikami M, Sugiyama T
J Clin Med. 2019 Jan 30;8(2). pii: E156. doi: 10.3390/jcm8020156.
Profile of treatment-related complications in women with clinical stage IB-IIB cervical cancer: A nationwide cohort study in Japan.
Machida H, Matsuo K, Furusawa A, Kita T, Kitagawa R, Mikami M.
PLoS One. 2019 Jan 7;14(1):e0210125. doi: 10.1371
Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067).
Matoda M, Takeshima N, Michimae H, Iwata T, Yokota H, Torii Y, Yamamoto Y, Takehara K, Nishio S, Takano H, Mizuno M, Takahashi Y, Takei Y, Hasegawa T, Mikami M, Enomoto T, Aoki D, Sugiyama T.
Gynecol Oncol. 2018 Apr 13. pii: S0090-8258(18)30286-5. doi: 10.1016/j.ygyno.2018.04.009.
Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer.
Matsuo K, Shimada M, Yamaguchi S, Kanao H, Nakanishi T, Saito T, Kamiura S, Iwata T, Mikami M, Sugiyama T.
Int J Cancer 2017 Oct 4. doi: 10.1002/ijc.31084.
Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer.
Matsuo K, Shimada M, Yokota H, Satoh T, Katabuchi H, Kodama S, Sasaki H, Matsumura N, Mikami M, Sugiyama T.
Oncotarget 2017 Nov 15;8(63):106866-106875. doi: 10.18632/oncotarget.22437. eCollection 2017 Dec 5
Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IB-IIB cervical cancer.
Matsuo K, Shimada M, Tsuyoshi Saito T, Takehara K, Tokunaga H, Watanabe Y, Todo Y, Morishige K, Mikami M, Sugiyama T.
J Gynecol Oncol. 2018 Jan 29(1) e11.doi: 10.3802/jgo.2018.29.e11.
The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Takekuma M, Mori K, Iida T, Kurihara K, Saitou M, Tokunaga H, Kawana K, Ikeda M, Satoh T, Saito T, Miyagi E, Nagai Y, Furusawa A, Kawano Y, Kawano K, Tabata T, Ota Y, Hayase R, Mikami M, Sugiyama T
Cancer Chemother Pharmacol. 2017 Aug 7. doi: 10.1007/s00280-017-3402.
Ovarian conservation for young women with clinical stage IB-IIB cervical cancer in Japan.
Matsuo K, Shimada M, Mikami M.
J Gynecol Oncol. 2017 Jul;28(4):e60. doi: 10.3802/jgo.2017.28.e60.
Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation.
Matsuo K, Shimada M, Aoki Y, Sakamoto M, Takeshima N, Fujiwara H, Matsumoto T, Mikami M, Sugiyama T.
Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30793.
Human Papillomavirus Test for Triage of Japanese Women With Low-Grade Squamous Intraepithelial Lesions.
Iwata T, Hasegawa T, Ochiai K, Takizawa K, Umezawa S, Kuramoto H, Ohmura M, Kubushiro K, Arai H, Sakamoto M, Motoyama T, Watanabe K, Aoki D.
Reprod Sci. 2015 Jun 19. pii: 1933719115589408.
Surgical Principles for Managing Stage IB2, IIA2, and IIB Uterine Cervical Cancer (Bulky Tumors) in Japan: A Survey of the Japanese Gynecologic Oncology Group.
Mikami M, Aoki Y, Sakamoto M, Shimada M, Takeshima N, Fujiwara H, Matsumoto T, Kita T, Takizawa K; Disease Committee of Uterine Cervical and Vulvar Cancer, Japanese Gynecologic Oncology Group.
International Journal of Gynecological Cancer. 24(7):1333-40, 2014 Sep.
Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100:a JGOG study
Sugiyama T, Fujiwara K, Ohashi Y, Yokota H, Hatae M, Ohno T, Nagai Y, Mitsuhashi N, Ochiai K, Noda K.
Annals of Oncology. 2014 May;25(5):1011-7
Current surgical principle for uterine cervical cancer of stages Ia2, Ib1, and IIa1 in Japan: a survey of the Japanese Gynecologic Oncology Group.
Mikami M. Aoki Y. Sakamoto M. Shimada M. Takeshima N. Fujiwara H. Matsumoto T. Kita T. Takizawa K.
International Journal of Gynecological Cancer. 2013; 23(9): 1655-60; quiz 1661-2.
Feasibility and Acute Toxicity of Concurrent Chemoradiotherapy (CCRT) With High-Dose Rate Intracavitary Brachytherapy (HDR-ICBT) and 40-mg/m2 Weekly Cisplatin for Japanese Patients With Cervical Cancer: Results of a Multi-Institutional Phase 2 Study (JGOG1066).
Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K; Cervical Cancer (Vulva Cancer) Committee of the Japanese Gynecologic Oncology Group (JGOG).
Int J Gynecol Cancer. 2012; 22: 1420-26.
Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).
Yamaguchi S, Nishimura R, Yaegashi N, Kiguchi K, Sugiyama T, Kita T, Kubushiro K, Kokawa K, Hiura M, Mizutani K, Yamamoto K, Takizawa K.
Oncol Rep. 2012; 28: 487-93.
Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: Efficacy and toxicity of a low cumulative radiation dose schedule.
Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K; Cervical Cancer (Vulva Cancer) Committee of the Japanese Gynecologic Oncology Group (JGOG).
Gynecol Oncol. 2012; 126: 211-6.
Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer.
Toita T, Kato S, Ishikura S, Tsujino K, Kodaira T, Uno T, Hatano K, Sakurai H, Niibe Y, Kazumoto T, Nishimura T, Kitagawa R, Fukutani M, Oguchi M, Umayahara K, Hirashima Y, Aoki Y, Takizawa K; and Disease Committee of Radiation Oncology, Japanese Gynecologic Oncology Group.
Int J Clin Oncol. 2011; 16 : 379-86.
Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study.
Yamamoto K, Kokawa K, Umesaki N, Nishimura R, Hasegawa K, Konishi I, Saji F, Nishida M, Noguchi H, Takizawa K.
Oncol Rep. 2009; 21: 1005-9.
Phase I study of irinotecan combined with mitomycin- C and 5-fluorouracil for gynecological malignancies; The JGOG Study.
Kokawa K, Umesaki N, Yamamoto K, Takizawa K, Konishi I, Hasegawa K; Japan Gynecologic Oncology Group.
Anticancer Res. 2008; 28: 2933-9.
Adjuvant oral 5-fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report.
Yamamoto K, Izumi R, Hasegawa K, Nakajima H, Ohashi K, Kudo R, Okuda H, Takahashi T, Origasa H, Sugimori H.
Int J Oncol. 2004; 24: 1175-9.
Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study.
Umesaki N, Fujii T, Nishimura R, Tanaka T, Nishida M, Fushiki H, Takizawa K, Yamamoto K, Hasegawa K, Izumi R; Japan Gynecologic Oncology Group.
Gynecol Oncol. 2004; 95: 127-32.
Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease.
Umesaki N, Izumi R, Fushiki H, Hasegawa K, Kono I, Nishida M, Noguchi H, Okuda H, Sugimori H, Takizawa K, Udagawa Y, Yamamoto K, Tanaka T, Noda K.
Gynecol Oncol.1999; 75: 142-4.
Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan.
Ikeda Y, Furusawa A, Kitagawa R, Tokinaga A, Ito F, Ukita M, Nomura H, Yamagami W, Tanabe H, Mikami M, Takeshima N, Yaegashi N.
J Gynecol Oncol. 2016 May;27(3):e29.

Uterine Cancer Committee （Click to expand）

Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H, Aoki D, Michimae H, Mizuno M, Nakai H, Arai M, Sasagawa M, Ushijima K, Sugiyama T, Saito M, Tokunaga H, Matoda M, Nakanishi T, Watanabe Y, Takahashi F, Saito T, Yaegashi N
JAMA Oncol. 2019 Mar 21. doi: 10.1001/jamaoncol.2019.0001.
Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group.
Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T.
Gynecol Oncol. 2016 Apr 14. pii: S0090-8258(16)30105-6.
How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey.
Yokoyama Y, Ito K, Takamatsu K, Takehara K, Nakanishi T, Harano K, Watari H, Susumu N, Aoki D, Saito T.
Int J Clin Oncol. 2015 Oct;20(5):997-1004. doi: 10.1007/s10147-015-0808-5. Epub 2015 Mar 6.
Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T.
Int J Clin Oncol. 2015 Jun 18.
Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, Jobo T, Hatae M, Hiura M, Yaegashi N.
Ann Oncol. 2011; 22: 636-42.
Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group(JGOG2044s).
Watanabe Y, Kitagawa R, Aoki D, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N; Disease Committee of Uterine Endometrial Cancer, Japanese Gynecologic Oncology Group.
Gynecol Oncol. 2009; 115: 456-9.
Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R; Japanese Gynecologic Oncology Group.
Gynecol Oncol. 2008; 108: 226-33.
Status of surgical treatment procedures for endometrial cancer in Japan: results of a Japanese Gynecologic Oncology Group survey.（JGOG2045s）
Watanabe Y, Aoki D, Kitagawa R, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N; Disease Committee of Uterine Endometrial Cancer, Japanese Gynecologic Oncology Group.
Gynecol Oncol. 2007; 105: 325-8.

Ovarian Cancer Committee （Click to expand）

An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T, Komiyama S, Kigawa J, Tanabe H, Kato K, Itamochi H, Fujiwara H, Kamiura S, Hamano T, Sugiyama T,
BMC Cancer. 2018 Jul 31;18(1):771. doi: 10.1186/s12885-018-4505-4.
(BMC Cancer) (PubMed)
Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)
Komiyama S, Kato K, Inokuchi Y, Takano H, Matsumoto T, Hongo A, Asai-Sato M, Arakawa A, Kamiura S, Tabata T, Takeshima N, Sugiyama T,
Int J Clin Oncol (2018). https://doi.org/10.1007/s10147-018-1319-y
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y, Suzuki N, Mikami M, Yaegashi N, Kato K, Yoshikawa H, Yokoyama Y, Tanabe H, Nishino K, Nomura H, Kim JW, Kim BG, Pignata S, Alexandre J, Green J, Isonishi S, Terauchi F, Fujiwara K, Aoki D.
J Clin Oncol. 2016 Aug 20;34(24):2881-7. doi: 10.1200/JCO.2016.66.9010. Epub 2016 Jul 11.
Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016).
Harano K. Terauchi F. Katsumata N. Takahashi F. Yasuda M. Takakura S. Takano M. Yamamoto Y. Sugiyama T..
Annals of Oncology. 2014; 25(1): 251-7.
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N. Yasuda M. Isonishi S. Takahashi F. Michimae H. Kimura E. Aoki D. Jobo T. Kodama S. Terauchi F. Sugiyama T. Ochiai K.
Lancet Oncology. 2013; 14(10): 1020-6.
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Ushijima K. Kamura T. Tamura K. Kuzuya K. Sugiyama T. Noda K. Ochiai K.
International Journal of Clinical Oncology. 2013; 18(1): 126-31.
Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.
Kumagai S, Sugiyama T, Shoji T, Michimae H, Katsumata N, Aoki D, Terauchi F, Jobo T, Ochiai K, Yasuda M.
Int J Gynecol Cancer. 2011; 21: 1585-91.
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Ushijima K, Kamura T, Tamura K, Kuzuya K, Sugiyama T, Noda K, Ochiai K.
Int J Clin Oncol. 2011 Nov 30. [Epub ahead of print]
Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, Noda K, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group.
Int J Gynecol Cancer. 2010; 20: 240-7.
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K; Japanese Gynecologic Oncology Group.
Lancet. 2009; 374: 1331-8.
Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
Katsumata N, Fujiwara Y, Kamura T, Nakanishi T, Hatae M, Aoki D, Tanaka K, Tsuda H, Kamiura S, Takehara K, Sugiyama T, Kigawa J, Fujiwara K, Ochiai K, Ishida R, Inagaki M, Noda K.
Jpn J Clin Oncol. 2008; 38: 777-85.